Literature DB >> 19101187

Intravitreal bevacizumab and triamcinolone treatment for choroidal neovascularization in Best disease.

Mehmet Cakir1, Osman Cekiç, O Faruk Yilmaz.   

Abstract

An 11-year-old girl with active subfoveal choroidal neovascularization associated with Best disease responded well to a single intravitreal injection of combined bevacizumab and triamcinolone acetonide. Choroidal neovascularization regressed, subretinal serous fluid resorbed, and visual acuity improved from 20/400 to 20/100. The patient remained stable for 6 months after injection.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19101187     DOI： 10.1016/j.jaapos.2008.06.014

Source DB:  PubMed          Journal:  J AAPOS        ISSN： 1091-8531            Impact factor:   1.220


  3 in total

1.  Intravitreal bevacizumab in choroidal neovascularization associated with Best's vitelliform dystrophy.

Authors:  Subrata Mandal; Subijay Sinha; Pradeep Venkatesh; Nagender Vashisht
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

2.  Conjunctival necrosis following a subconjunctival injection of triamcinolone acetonide in a child.

Authors:  Chong Ying-Jiun; Wong Chee-Kuen; Ismail Shatriah
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Jan-Mar

3.  Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.

Authors:  Olga Dratviman-Storobinsky; Bat-Chen R Avraham-Lubin; Murat Hasanreisoglu; Nitza Goldenberg-Cohen
Journal:  Mol Vis       Date:  2009-11-13       Impact factor: 2.367
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.